Fenretinide

haptoglobin-related protein ; Homo sapiens







219 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 33423090 A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors. 2021 Apr 1
2 32266855 Mixed micelles of TPGS and Soluplus® for co-delivery of paclitaxel and fenretinide: in vitro and in vivo anticancer study. 2020 Sep 2
3 32366203 Fenretinide-polyethylene glycol (PEG) conjugate with improved solubility enhanced cytotoxicity to cancer cell and potent in vivo efficacy. 2020 Oct 1
4 32497314 Design, Synthesis, Radiosynthesis and Biological Evaluation of Fenretinide Analogues as Anticancer and Metabolic Syndrome-Preventive Agents. 2020 Aug 19 1
5 30836314 Hydrophilic interaction liquid chromatography-tandem mass spectrometric approach for simultaneous determination of safingol and D-erythro-sphinganine in human plasma. 2019 Apr 1 1
6 31484706 Fenretinide via NOXA Induction, Enhanced Activity of the BCL-2 Inhibitor Venetoclax in High BCL-2-Expressing Neuroblastoma Preclinical Models. 2019 Dec 1
7 29767236 Fenretinide inhibits the proliferation and migration of human liver cancer HepG2 cells by downregulating the activation of myosin light chain kinase through the p38‑MAPK signaling pathway. 2018 Jul 2
8 30061204 4-HPR Is an Endoplasmic Reticulum Stress Aggravator and Sensitizes Breast Cancer Cells Resistant to TRAIL/Apo2L. 2018 Aug 1
9 30251395 Cytotoxic activity of difluoromethylornithine compared with fenretinide in neuroblastoma cell lines. 2018 Dec 1
10 27701038 Analysis of fenretinide and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics. 2017 Jan 5 2
11 28179290 Fumonisin B1 Inhibits Endoplasmic Reticulum Stress Associated-apoptosis After FoscanPDT Combined with C6-Pyridinium Ceramide or Fenretinide. 2017 Feb 1
12 28275870 Synthesis of short retinoidal amides related to fenretinide: antioxidant activities and differentiation-inducing ability. 2017 Apr 1
13 28340497 P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models. 2017 Jul 15 1
14 28429653 Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives. 2017 Jun 1
15 28448568 Inhibitory effects of fenretinide metabolites N-[4-methoxyphenyl]retinamide (MPR) and 4-oxo-N-(4-hydroxyphenyl)retinamide (3-keto-HPR) on fenretinide molecular targets β-carotene oxygenase 1, stearoyl-CoA desaturase 1 and dihydroceramide Δ4-desaturase 1. 2017 5
16 28988109 Nuclear import inhibitor N-(4-hydroxyphenyl) retinamide targets Zika virus (ZIKV) nonstructural protein 5 to inhibit ZIKV infection. 2017 Dec 2 1
17 27085050 Enhanced apoptotic cancer cell killing after Foscan photodynamic therapy combined with fenretinide via de novo sphingolipid biosynthesis pathway. 2016 Jun 1
18 27367907 Fenretinide (4-HPR) Targets Caspase-9, ERK 1/2 and the Wnt3a/β-Catenin Pathway in Medulloblastoma Cells and Medulloblastoma Cell Spheroids. 2016 3
19 27530131 Reactive Oxygen Species Mediates the Synergistic Activity of Fenretinide Combined with the Microtubule Inhibitor ABT-751 against Multidrug-Resistant Recurrent Neuroblastoma Xenografts. 2016 Nov 1
20 25313218 The bioactive lipid 4-hydroxyphenyl retinamide inhibits flavivirus replication. 2015 Jan 2
21 25576804 Colloidal silver nanoparticles improve anti-leukemic drug efficacy via amplification of oxidative stress. 2015 Feb 1 1
22 26220867 Dynamics of ceramide generation and metabolism in response to fenretinide--Diversity within and among leukemia. 2015 Oct 2
23 24253178 p75 neurotrophin receptor and fenretinide-induced signaling in neuroblastoma. 2014 Feb 2
24 24392637 The oxidation states of DJ-1 dictate the cell fate in response to oxidative stress triggered by 4-hpr: autophagy or apoptosis? 2014 Oct 1 2
25 24755119 Additive enhancement of apoptosis by TRAIL and fenretinide in metastatic breast cancer cells in vitro. 2014 May 1
26 23052481 Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity. 2013 Apr 2
27 23792118 Enhanced anti-tumor and anti-angiogenic efficacy of a novel liposomal fenretinide on human neuroblastoma. 2013 Sep 28 1
28 23813912 Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium. 2013 Nov 1
29 24040340 C22:0- and C24:0-dihydroceramides confer mixed cytotoxicity in T-cell acute lymphoblastic leukemia cell lines. 2013 1
30 21964808 The impact of retinoic acid treatment on the sensitivity of neuroblastoma cells to fenretinide. 2012 Jan 2
31 22183330 The mechanism of fenretinide (4-HPR) inhibition of β-carotene monooxygenase 1. New suspect for the visual side effects of fenretinide. 2012 1
32 22221098 Enhanced anti-neuroblastoma activity of a fenretinide complexed form after intravenous administration. 2012 Feb 1
33 22427354 Evaluation of a mucoadhesive fenretinide patch for local intraoral delivery: a strategy to reintroduce fenretinide for oral cancer chemoprevention. 2012 May 2
34 22428532 Dihydroceramide accumulation and reactive oxygen species are distinct and nonessential events in 4-HPR-mediated leukemia cell death. 2012 Apr 1
35 22488409 N-(4-hydroxyphenyl)retinamide inhibits breast cancer cell invasion through suppressing NF-KB activation and inhibiting matrix metalloproteinase-9 expression. 2012 Sep 1
36 22498172 Alterations in expression of specific microRNAs by combination of 4-HPR and EGCG inhibited growth of human malignant neuroblastoma cells. 2012 May 15 1
37 22500077 Fenretinide (4-HPR): a preventive chance for women at genetic and familial risk? 2012 2
38 22532987 Fenretinide cytotoxicity is independent of both constitutive and pharmacologically modulated glutathione levels in pediatric acute lymphoblastic leukemia cells cultured at hypoxia. 2012 Jun 1
39 22761939 AF1q: a novel mediator of basal and 4-HPR-induced apoptosis in ovarian cancer cells. 2012 1
40 21054342 Characterization of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases. 2011 Feb 1
41 21072519 Cytotoxic responses to N-(4-hydroxyphenyl)retinamide in human pancreatic cancer cells. 2011 Aug 1
42 21498721 Phase I trial of fenretinide lym-x-sorb oral powder in adults with solid tumors and lymphomas. 2011 Mar 2
43 21543327 Identification of dihydroceramide desaturase as a direct in vitro target for fenretinide. 2011 Jul 15 1
44 21557271 Inhibition of acid ceramidase by a 2-substituted aminoethanol amide synergistically sensitizes prostate cancer cells to N-(4-hydroxyphenyl) retinamide. 2011 Jul 1
45 21723035 TMEM14A inhibits N-(4-hydroxyphenyl)retinamide-induced apoptosis through the stabilization of mitochondrial membrane potential. 2011 Oct 28 1
46 21822457 N-(4-Hydroxyphenyl) Retinamide Potentiated Anti-tumor Efficacy of Genistein in Human Ewing's Sarcoma Xenografts. 2011 Apr 1
47 21908574 Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group. 2011 Nov 1 1
48 21933888 Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma. 2011 Nov 15 1
49 21951911 In vitro activities of novel 4-HPR derivatives on a panel of rhabdoid and other tumor cell lines. 2011 Sep 27 2
50 22061047 Evaluation of bioactive sphingolipids in 4-HPR-resistant leukemia cells. 2011 Nov 7 2